Literature DB >> 9949181

Cytogenetic profile of lymphoma of follicle mantle lineage: correlation with clinicobiologic features.

A Cuneo1, R Bigoni, G M Rigolin, M G Roberti, A Bardi, N Piva, R Milani, F Bullrich, M L Veronese, C Croce, F Birg, H Döhner, A Hagemeijer, G Castoldi.   

Abstract

Conventional chromosome analysis (CCA) and interphase fluorescence in situ hybridization (FISH) was performed in 42 patients with mantle-cell lymphoma (MCL), with BCL1 rearrangement. The t(11;14)(q13;q32) or 11q abnormalities were detected by CCA in 34 cases, 20 of which had additional aberrations. A normal karyotype was observed in 8 cases. Probes detecting the chromosome aberrations that were observed in at least 3 cases by CCA, ie, +12, 13q14 deletion, and 17p deletion, were used for interphase FISH analysis. FISH detected total or partial +12, 13q14 deletion and 17p- in 28.5%, 52.4%, and 26% of the cases, respectively. The presence of these anomalies was not a function of karyotype complexity. Based on the results of CCA/FISH, three groups of increasing karyotype complexity were recognized: group 1, including 11 patients without detectable aberrations in addition to BCL1 rearrangement; group 2, including 14 patients with 1 to 2 additional anomalies; and group 3, including 17 patients with three or more additional anomalies. Clinical parameters associated with shorter survival were male sex (P =.006) and primary lymph-node involvement compared with primary bone marrow involvement (P =.015). Trisomy 12 was the only single cytogenetic parameter predictive of a poor prognosis (P =.006) and the best prognostic indicator was the derived measure of karyotype complexity (P <.0001), which maintained statistical significance in multivariate analysis (P<.0001). We arrived at the following conclusions: 13q14 deletion occurs at a high incidence in MCL; 17p deletion and total/partial +12 are relatively frequent events in MCL, the latter aberration being associated with a shorter survival; and the degree of karyotype complexity has a strong impact on prognosis in this neoplasia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9949181

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.

Authors:  I Brian Greenwell; Ashley D Staton; Michael J Lee; Jeffrey M Switchenko; Debra F Saxe; Joseph J Maly; Kristie A Blum; Natalie S Grover; Stephanie P Mathews; Max J Gordon; Alexey V Danilov; Narendranath Epperla; Timothy S Fenske; Mehdi Hamadani; Steven I Park; Christopher R Flowers; Jonathon B Cohen
Journal:  Cancer       Date:  2018-03-26       Impact factor: 6.860

2.  Fluorescence PCR quantification of cyclin D1 expression.

Authors:  Kojo S J Elenitoba-Johnson; Sandra D Bohling; Stephen D Jenson; Zhaosheng Lin; Kimberly A Monnin; Megan S Lim
Journal:  J Mol Diagn       Date:  2002-05       Impact factor: 5.568

3.  Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature.

Authors:  Itziar Salaverria; Andreas Zettl; Sílvia Beà; Victor Moreno; Joan Valls; Elena Hartmann; German Ott; George Wright; Armando Lopez-Guillermo; Wing C Chan; Dennis D Weisenburger; Randy D Gascoyne; Thomas M Grogan; Jan Delabie; Elaine S Jaffe; Emili Montserrat; Hans-Konrad Muller-Hermelink; Louis M Staudt; Andreas Rosenwald; Elias Campo
Journal:  J Clin Oncol       Date:  2007-02-12       Impact factor: 44.544

4.  Mantle cell lymphoma: improved diagnostics using a combined approach of immunohistochemistry and identification of t(11;14)(q13;q32) by polymerase chain reaction and fluorescence in situ hybridization.

Authors:  Roman Kodet; Marcela Mrhalová; Lenka Krsková; Jan Soukup; Vít Campr; Tomás Neskudla; Peter Szépe; Lukás Plank
Journal:  Virchows Arch       Date:  2003-05-01       Impact factor: 4.064

5.  Identified hidden genomic changes in mantle cell lymphoma using high-resolution single nucleotide polymorphism genomic array.

Authors:  Norihiko Kawamata; Seishi Ogawa; Saskia Gueller; Samuel H Ross; Thien Huynh; John Chen; Andrew Chang; Shayan Nabavi-Nouis; Nairi Megrabian; Reiner Siebert; Jose A Martinez-Climent; H Phillip Koeffler
Journal:  Exp Hematol       Date:  2009-05-27       Impact factor: 3.084

Review 6.  The pathologic diagnosis of mantle cell lymphoma.

Authors:  Shaoying Li; Jie Xu; M James You
Journal:  Histol Histopathol       Date:  2021-06-11       Impact factor: 2.303

7.  Mantle cell lymphoma and involvement of the orbit and ocular adnexa.

Authors:  Elham Vali Khojeini; Benjamin H Durham; Mingyi Chen
Journal:  Case Rep Pathol       Date:  2013-04-04

8.  De Novo CD5 Negative Blastic Mantle Cell Lymphoma Presented with Massive Bone Marrow Necrosis without Adenopathy or Organomegaly.

Authors:  Ghaleb Elyamany; Ali Matar Alzahrani; Eman Al Mussaed; Hassan Aljasem; Sultan Alotaibi; Hatem Elghezal
Journal:  Case Rep Hematol       Date:  2015-08-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.